Clinical guideline
European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia
Leukemia · 2020
Studies and guidelines: Leukaemia
18 items with a structured summary · Leukaemia: the complete guide
Clinical trial · Phase 3
Follow-up from the A041202 study shows continued efficacy of ibrutinib regimens for older adults with CLL
Blood · 2024
76% (ibrutinib), 76% (IR), 47% (BR)48-month progression-free survival
Clinical trial · Phase 3
Sorafenib maintenance after allogeneic haemopoietic stem-cell transplantation in patients with FLT3-ITD acute myeloid leukaemia: long-term follow-up of an open-label, multicentre, randomised, phase 3 trial
Lancet Haematol · 2023
72.0% vs 55.9%Five-year overall survival
Clinical trial
Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial
The Lancet Oncology · 2018
27 monthsMedian follow-up (755 patients)
Review article
Acute Lymphoblastic Leukemia in Children
N Engl J Med · 2015
Clinical trial
Randomized Comparison of Cooked and Noncooked Diets in Patients Undergoing Remission Induction Therapy for Acute Myeloid Leukemia
JCO · 2008
29% in the cooked group vs 35% in the raw groupMajor infection
Clinical trial · Phase 3
Ponatinib vs Imatinib in Frontline Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia
JAMA · 2024
34.4% (53 of 154) vs 16.7% (13 of 78)MRD-negative complete remission (primary endpoint)
Clinical trial · Phase 3
Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia
N Engl J Med · 2016
80.7% vs 29.4%Complete remission rate (first 218 patients)
Clinical trial · Phase 3
Retinoic acid and arsenic trioxide for acute promyelocytic leukemia
N Engl J Med · 2013
97% vs 86%2-year event-free survival
Clinical trial · Phase 3
Asciminib demonstrates superior efficacy and safety in newly diagnosed chronic myeloid leukemia in the ASC4FIRST trial
Blood · 2026
74.1% vs 52.0%MMR at week 96 (versus all TKIs)
Clinical trial
Menin inhibition with revumenib for NPM1 -mutated relapsed or refractory acute myeloid leukemia: the AUGMENT-101 study
Blood · 2025
23.4%CR + CRh rate (64 evaluable adult patients)
Clinical trial
Menin Inhibition With Revumenib for KMT2A-Rearranged Relapsed or Refractory Acute Leukemia (AUGMENT-101)
J Clin Oncol · 2025
22.8%CR + CRh
Clinical trial · Phase 2
Ziftomenib in Relapsed or Refractory NPM1 -Mutated AML
J Clin Oncol · 2025
22%CR/CRh rate (primary endpoint)
Clinical trial · Phase 3
Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): a randomised, double-blind, placebo-controlled, phase 3 trial
Lancet · 2023
31.9 vs 15.1 monthsMedian overall survival
Clinical trial · Phase 3
Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia
N Engl J Med · 2023
HR 0.65Progression-free survival
Clinical trial · Phase 2
KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study
The Lancet · 2021
Successfully manufactured for 65 patients (92%); administered to 55 patients (77%) of the 71 enrolledManufacture and administration of KTE-X19
Clinical trial · Phase 3
Asciminib in Newly Diagnosed Chronic Myeloid Leukemia
N Engl J Med · 2024
67.7% vs 49.0%MMR at week 48 (overall)
Clinical trial · Phase 3
Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL
N Engl J Med · 2018
87% vs 74%2-year PFS: ibrutinib vs BR
Nothing found.